title: Successful Treatment of Myocardial Infarction in an Infant With Kawasaki Disease.
abstract: Although early treatment with intravenous immunoglobulin reduces the risk of coronary artery aneurysms, in refractory cases of Kawasaki disease, myocardial infarction can result from thrombosis of coronary artery aneurysms. Early recognition of myocardial infarction from Kawasaki disease myocarditis can reduce morbidity and mortality. This report describes successful treatment of myocardial infarction from coronary thrombosis in an infant with Kawasaki disease using intravenous tissue plasminogen activator and abciximab.
authors.affiliation: Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, CO, USA pei-ni.jone@childrenscolorado.org.
authors.forename: Pei-Ni
authors.initials: PN
authors.lastname: Jone
authors.affiliation: Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, CO, USA.
authors.forename: Daniel
authors.initials: D
authors.lastname: Tapia
authors.affiliation: Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, CO, USA.
authors.forename: Jesse
authors.initials: J
authors.lastname: Davidson
authors.affiliation: Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, CO, USA.
authors.forename: Thomas E
authors.initials: TE
authors.lastname: Fagan
authors.affiliation: Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, CO, USA.
authors.forename: Lorna
authors.initials: L
authors.lastname: Browne
authors.affiliation: Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, CO, USA.
authors.forename: Richard John
authors.initials: RJ
authors.lastname: Ing
authors.affiliation: Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, CO, USA.
authors.forename: Joseph
authors.initials: J
authors.lastname: Kay
mesh_terms: D000077284:Abciximab; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use; D003328:Coronary Thrombosis / Q000150:complications* / Q000188:drug therapy / Q000209:etiology; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage / Q000627:therapeutic use; D007223:Infant; D008297:Male; D009080:Mucocutaneous Lymph Node Syndrome / Q000150:complications*; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000209:etiology; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D005343:Fibrinolytic Agents; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D010959:Tissue Plasminogen Activator; D000077284:Abciximab
keywords: Kawasaki disease; abciximab; coronary artery aneurysms; coronary artery thrombosis; myocardial infarction; thrombolytics